We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Multiple Oral Dose Safety, Tolerability And Pharmacokinetic Study Of PF-04287881 In Healthy Adult Subjects

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01026545
First Posted: December 4, 2009
Last Update Posted: May 4, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Pfizer
  Purpose

This study is a randomized, investigator blind, subject blind, sponsor-open, placebo controlled, multiple dose escalating, sequential, parallel cohort study of PF-04287881. Subjects will undergo screening procedures within 28 days prior to dosing. At least 1 day after the Screening visit, eligible subjects who meet the entry criteria will be admitted to the Clinical Research Unit (CRU) and confined in the unit until discharge on Day 15.

Approximately 60 healthy volunteers (20 volunteers of Japanese origin for Cohorts 5 and 6), 18 to 55 years of age, males and females (women of non childbearing potential only) will be enrolled and randomized in a 4:1 ratio to treatment with either PF-04287881 or placebo within each cohort. Each cohort will have a 10 day dosing period and each will consist of 10 subjects (8 active and 2 placebo). In each cohort, each subject will receive a single daily oral dose of either placebo or PF-04287881 under fasted state for 10 days.


Condition Intervention Phase
Respiratory Tract Infections Drug: PF-04287881 Drug: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Official Title: A Phase 1, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-04287881 After Administration Of Multiple Escalating Oral Doses To Healthy Adult Subjects

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Standard safety assessments including assessment of AEs, laboratory tests, ECGs, and vital signs. [ Time Frame: Screening, Dosing days 1-10, through follow-up ]
  • The primary pharmacokinetic endpoints to be evaluated for PF-04287881 include Cmax, Tmax, and AUC(0-24) on Day 1 and Day 10. [ Time Frame: Day 1 and 10 ]

Secondary Outcome Measures:
  • Secondary parameters include AUCinf and t1/2 as data permit, apparent oral clearance (CL/F), apparent volume of distribution (Vz/F) and accumulation ratio (Rac). [ Time Frame: Days 1, 5 and 10 ]
  • Urine concentrations of PF 04287881 in Cohorts 2 and 5 will be used to determine total amount excreted (Ae), %Ae relative to dose given and renal clearance (CLR). [ Time Frame: Day 10 ]
  • Concentrations of PF 04287881 will be measured in white blood cell (WBC) polymorphonuclear cells (PMNs) in Cohorts 2 and 5 to determine total exposure in WBC. [ Time Frame: Days 1 and 10 ]
  • Plasma samples from Cohort 2 will be used for exploratory investigation of circulating metabolites. [ Time Frame: Days 1 and 10 ]

Enrollment: 39
Study Start Date: December 2009
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort 1 Drug: PF-04287881
500 mg once daily for 10 days
Drug: Placebo
To match 500 mg dose once daily for 10 days
Experimental: Cohort 2 Drug: PF-04287881
750 mg once daily for 10 days
Drug: Placebo
To match 750 mg dose once daily for 10 days
Experimental: Cohort 3 Drug: PF-04287881
1100 mg once daily for 10 days
Drug: Placebo
To match 1100 mg dose once daily for 10 days
Experimental: Cohort 4 (optional)
If intermediate or repeat dose level is needed; dose will not exceed 1100 mg.
Drug: PF-04287881
Optional cohort with dose not greater than 1100 mg
Drug: Placebo
Optional cohort to match dose not greater than 1100 mg
Experimental: Cohort 5 (Japanese) Drug: PF-04287881
750 mg dose once daily for 10 days
Drug: Placebo
To match 750 mg dose once daily for 10 days
Experimental: Cohort 6 (Japanese) Drug: PF-04287881
1100 mg dose once daily for 10 days
Drug: Placebo
To match 1100 mg dose once daily for 10 days

Detailed Description:
Following a Serious Adverse Event (potential Hy's Law case), a risk-benefit assessment review of all preliminary safety data, and a review by Pfizer's internal hepatic injury advisory panel, it was concluded that PF-04287881 had an unacceptable therapeutic window. The FDA was notified of our intention to discontinue development as of 09April2010.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Volunteers willing and able to be confined to the Clinical Research Unit and comply with study schedule.
  • Women of non-childbearing potential only.
  • Japanese subjects must have 4 Japanese grandparents who were born in Japan.

Exclusion Criteria:

  • Previous antibiotic use within 14 days prior to dosing.
  • Use of antibiotics during hospitalization within 90 days prior to dosing.
  • History of hypersensitivity to macrolides or ketolides.
  • Presence of clinically significant eye conditions (other than corrective lenses).
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01026545


Locations
United States, Connecticut
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT01026545     History of Changes
Other Study ID Numbers: B0581002
First Submitted: December 3, 2009
First Posted: December 4, 2009
Last Update Posted: May 4, 2011
Last Verified: May 2011

Keywords provided by Pfizer:
safety
tolerability
pharmacokinetics
multiple-dose
macrolide

Additional relevant MeSH terms:
Respiratory Tract Infections
Infection
Respiratory Tract Diseases